Incidence, Prevalence, and Mortality of Dermatomyositis in Adults Determined
Using the ACR/EULAR criteria, researchers studied the population-based incidence, prevalence, and mortality of dermatomyositis in adults.
Myopathy
Immune-Related Myositis: A Rare But Important Immune-Related Adverse Event
Shashank Suresh, MD, takes us on a deep dive into the importance of immune-related adverse events, including immune-related myositis, which can be triggered by immune checkpoint inhibitor therapy.
Novel GLP-1 Receptor Agonist Designated Orphan Drug for Polymyositis
The FDA has granted Orphan Drug designation to PF1801 for the treatment of polymyositis.
SARS-CoV-2 May Be Linked to Immune-Mediated Myopathy
In this case-control autopsy series, study researchers evaluated skeletal muscle and myocardial inflammations in patients with severe COVID-19 who died.
Integrating Clinical and Laboratory, Biopsy Findings May Help Predict Prognosis of Juvenile Dermatomyositis
Researchers assessed clinical features, muscle biopsy scores, and myositis-specific antibody profiles in juvenile dermatomyositis, and their association with disease outcomes and treatment responses in patients.
Creatine Supplementation May Be Safe, Well Tolerated in Patients With Juvenile Dermatomyositis
Researchers aimed to evaluate the feasibility of studying creatine in juvenile dermatomyositis and to determine the effect of creatine on muscle function and metabolism.
Pharmacologic Management of Type 2 Diabetes May Improve Concurrent Polymyalgia Rheumatica Symptoms
The study authors’ goal was to raise the possibility that some patients with polymyalgia rheumatica and type 2 diabetes mellitus can avoid glucocorticoid treatment.
Evidence Supports Content Validity of Patient-Reported Outcome Measures in Inflammatory Myositis
Researchers investigated the content validity of patient-reported outcome measures in patients with idiopathic inflammatory myopathies.
Cancer Screening Strategies in Rheumatic Diseases: Expert Perspectives
Experts highlight the need for cancer screening strategies in patients with rheumatic diseases.
Examining Treatment Options for Statin-Induced Anti-HMGCR Myopathy
A triple steroid/intravenous immunoglobulin/steroid-sparing immunosuppressant induction strategy was effective for the treatment of statin-induced anti-HMGCR myopathy.
- Loading...
Loading...
Next post in Inflammatory Myopathy
Loading... 
Loading...